| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 43 | 2022 | 188 | 9.960 |
Why?
|
| Monocytes | 23 | 2022 | 119 | 8.260 |
Why?
|
| Atherosclerosis | 20 | 2022 | 693 | 5.650 |
Why?
|
| Glutathione | 16 | 2018 | 37 | 2.670 |
Why?
|
| Oxidative Stress | 15 | 2022 | 223 | 2.290 |
Why?
|
| Chemotaxis, Leukocyte | 6 | 2019 | 18 | 2.180 |
Why?
|
| Lipoproteins, LDL | 16 | 2014 | 77 | 2.150 |
Why?
|
| Oxidation-Reduction | 19 | 2022 | 250 | 1.930 |
Why?
|
| Glutaredoxins | 6 | 2022 | 9 | 1.900 |
Why?
|
| Mice | 38 | 2022 | 2368 | 1.890 |
Why?
|
| Receptors, LDL | 11 | 2021 | 64 | 1.880 |
Why?
|
| Dual Specificity Phosphatase 1 | 4 | 2018 | 29 | 1.780 |
Why?
|
| Chemotaxis | 5 | 2019 | 23 | 1.680 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 56 | 1.640 |
Why?
|
| Macrophages, Peritoneal | 6 | 2016 | 19 | 1.590 |
Why?
|
| Animals | 51 | 2022 | 7297 | 1.590 |
Why?
|
| Triterpenes | 3 | 2018 | 4 | 1.560 |
Why?
|
| Reactive Oxygen Species | 11 | 2022 | 158 | 1.540 |
Why?
|
| Positron-Emission Tomography | 3 | 2017 | 172 | 1.530 |
Why?
|
| Aortic Diseases | 3 | 2018 | 54 | 1.520 |
Why?
|
| Mice, Inbred C57BL | 17 | 2022 | 711 | 1.320 |
Why?
|
| Cells, Cultured | 22 | 2016 | 799 | 1.270 |
Why?
|
| Sulfhydryl Compounds | 5 | 2021 | 33 | 1.230 |
Why?
|
| Signal Transduction | 11 | 2017 | 666 | 1.160 |
Why?
|
| Aorta | 5 | 2018 | 103 | 1.070 |
Why?
|
| Mice, Knockout | 13 | 2021 | 425 | 1.070 |
Why?
|
| Oxygen | 4 | 2013 | 139 | 0.990 |
Why?
|
| Obesity | 3 | 2022 | 1063 | 0.960 |
Why?
|
| Mitochondria | 4 | 2016 | 174 | 0.860 |
Why?
|
| Inflammation | 7 | 2019 | 507 | 0.860 |
Why?
|
| Protective Agents | 1 | 2022 | 4 | 0.850 |
Why?
|
| Stress, Physiological | 4 | 2017 | 44 | 0.820 |
Why?
|
| Cell Adhesion | 5 | 2017 | 103 | 0.800 |
Why?
|
| Apoptosis | 8 | 2015 | 337 | 0.740 |
Why?
|
| Chemokine CCL2 | 6 | 2019 | 47 | 0.720 |
Why?
|
| Disease Models, Animal | 11 | 2018 | 980 | 0.720 |
Why?
|
| Glutathione Reductase | 4 | 2007 | 9 | 0.720 |
Why?
|
| Humans | 46 | 2019 | 29093 | 0.690 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 72 | 0.690 |
Why?
|
| Vitamin E | 4 | 2001 | 21 | 0.680 |
Why?
|
| Glucose | 2 | 2016 | 163 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2017 | 37 | 0.650 |
Why?
|
| Proteins | 2 | 2016 | 140 | 0.630 |
Why?
|
| Dyslipidemias | 1 | 2018 | 52 | 0.630 |
Why?
|
| Glutamine | 1 | 2017 | 6 | 0.630 |
Why?
|
| Deoxyglucose | 1 | 2017 | 16 | 0.620 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2016 | 5 | 0.600 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 24 | 0.590 |
Why?
|
| Cell Line | 11 | 2016 | 449 | 0.590 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2011 | 51 | 0.570 |
Why?
|
| Cues | 1 | 2016 | 67 | 0.550 |
Why?
|
| Doxorubicin | 2 | 2006 | 55 | 0.540 |
Why?
|
| Phenotype | 4 | 2019 | 629 | 0.520 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2010 | 50 | 0.520 |
Why?
|
| Wound Healing | 4 | 2013 | 182 | 0.500 |
Why?
|
| 14-3-3 Proteins | 1 | 2014 | 4 | 0.500 |
Why?
|
| Foam Cells | 5 | 2005 | 11 | 0.500 |
Why?
|
| Lipoproteins | 4 | 2006 | 82 | 0.490 |
Why?
|
| Female | 16 | 2022 | 18164 | 0.460 |
Why?
|
| Gold | 4 | 2012 | 15 | 0.410 |
Why?
|
| Lipoproteins, HDL | 3 | 2010 | 247 | 0.410 |
Why?
|
| Platelet Activating Factor | 6 | 1994 | 14 | 0.410 |
Why?
|
| Dinoprostone | 5 | 1994 | 37 | 0.410 |
Why?
|
| Actins | 4 | 2014 | 52 | 0.400 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 18 | 0.400 |
Why?
|
| Heart Failure | 1 | 2017 | 568 | 0.400 |
Why?
|
| Venae Cavae | 1 | 2010 | 3 | 0.390 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 21 | 0.390 |
Why?
|
| Male | 19 | 2022 | 17807 | 0.380 |
Why?
|
| Diabetic Angiopathies | 1 | 2011 | 137 | 0.380 |
Why?
|
| Cholesterol | 4 | 2005 | 229 | 0.360 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2016 | 40 | 0.360 |
Why?
|
| Transforming Growth Factor beta | 3 | 2016 | 66 | 0.350 |
Why?
|
| Cholesterol Esters | 4 | 2004 | 37 | 0.350 |
Why?
|
| Time Factors | 8 | 2014 | 2001 | 0.350 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 59 | 0.340 |
Why?
|
| Receptors, Immunologic | 3 | 2005 | 18 | 0.320 |
Why?
|
| Hydrogen Peroxide | 4 | 2016 | 81 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 200 | 0.310 |
Why?
|
| Cell Death | 5 | 2010 | 71 | 0.310 |
Why?
|
| Cell Differentiation | 6 | 2018 | 436 | 0.310 |
Why?
|
| Arteriosclerosis | 4 | 2005 | 116 | 0.300 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2007 | 7 | 0.300 |
Why?
|
| Lipid Metabolism | 4 | 2005 | 100 | 0.300 |
Why?
|
| Lipopolysaccharides | 8 | 2006 | 107 | 0.290 |
Why?
|
| Transfection | 6 | 2014 | 192 | 0.290 |
Why?
|
| Kidney Diseases | 1 | 2009 | 239 | 0.290 |
Why?
|
| Oxidoreductases | 1 | 2006 | 20 | 0.280 |
Why?
|
| Interleukin-10 | 1 | 2006 | 30 | 0.280 |
Why?
|
| Interleukin-6 | 2 | 2006 | 225 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 641 | 0.270 |
Why?
|
| Adenoviridae | 3 | 2007 | 61 | 0.270 |
Why?
|
| Retina | 2 | 2016 | 50 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 73 | 0.260 |
Why?
|
| Energy Metabolism | 3 | 2015 | 139 | 0.250 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 87 | 0.250 |
Why?
|
| Caspases | 2 | 2003 | 31 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 2 | 2006 | 518 | 0.250 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 481 | 0.230 |
Why?
|
| Endothelial Cells | 3 | 2015 | 179 | 0.230 |
Why?
|
| Tomography, Optical Coherence | 2 | 2014 | 42 | 0.230 |
Why?
|
| Peroxides | 1 | 2003 | 31 | 0.220 |
Why?
|
| Phosphorylation | 2 | 2014 | 225 | 0.220 |
Why?
|
| Cell Culture Techniques | 2 | 2006 | 165 | 0.220 |
Why?
|
| Lipids | 4 | 2012 | 209 | 0.220 |
Why?
|
| Metal Nanoparticles | 2 | 2012 | 14 | 0.210 |
Why?
|
| Stilbenes | 2 | 2012 | 25 | 0.210 |
Why?
|
| Histone Deacetylase 2 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2016 | 100 | 0.200 |
Why?
|
| Gene Transfer Techniques | 2 | 2004 | 69 | 0.190 |
Why?
|
| Models, Biological | 6 | 2006 | 373 | 0.190 |
Why?
|
| Nanoparticles | 2 | 2012 | 47 | 0.190 |
Why?
|
| Computational Biology | 2 | 2019 | 86 | 0.180 |
Why?
|
| Basement Membrane | 1 | 2019 | 7 | 0.180 |
Why?
|
| Macrophage Activation | 2 | 2016 | 9 | 0.180 |
Why?
|
| Cell Count | 1 | 2019 | 50 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 863 | 0.180 |
Why?
|
| Extracellular Space | 2 | 2016 | 25 | 0.180 |
Why?
|
| Metabolomics | 1 | 2019 | 45 | 0.180 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 51 | 0.170 |
Why?
|
| Genomics | 1 | 2019 | 82 | 0.170 |
Why?
|
| Central Nervous System | 1 | 2019 | 29 | 0.170 |
Why?
|
| Microscopy, Confocal | 2 | 2012 | 62 | 0.170 |
Why?
|
| Neuroglia | 1 | 2019 | 29 | 0.170 |
Why?
|
| Proteomics | 1 | 2019 | 92 | 0.170 |
Why?
|
| Cell Movement | 2 | 2017 | 161 | 0.170 |
Why?
|
| Diet | 1 | 2021 | 354 | 0.170 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2016 | 27 | 0.170 |
Why?
|
| Dehydroascorbic Acid | 1 | 1998 | 1 | 0.170 |
Why?
|
| Thiocarbamates | 2 | 2010 | 6 | 0.170 |
Why?
|
| Tubulin | 1 | 2018 | 10 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2000 | 251 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 43 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2018 | 32 | 0.160 |
Why?
|
| Spleen | 2 | 2010 | 82 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 2 | 1994 | 7 | 0.160 |
Why?
|
| Autoradiography | 1 | 2017 | 47 | 0.160 |
Why?
|
| Microscopy, Phase-Contrast | 2 | 2015 | 9 | 0.150 |
Why?
|
| Weight Gain | 1 | 2018 | 108 | 0.150 |
Why?
|
| Dementia, Vascular | 1 | 2017 | 13 | 0.150 |
Why?
|
| Chromatography, Thin Layer | 1 | 1997 | 8 | 0.150 |
Why?
|
| Up-Regulation | 3 | 2014 | 183 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 2 | 2008 | 65 | 0.150 |
Why?
|
| Fetus | 1 | 2017 | 78 | 0.150 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 162 | 0.150 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2016 | 6 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 95 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 88 | 0.150 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 8 | 0.140 |
Why?
|
| Pericytes | 1 | 2016 | 28 | 0.140 |
Why?
|
| Triglycerides | 1 | 1997 | 214 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2016 | 64 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2016 | 56 | 0.140 |
Why?
|
| Refractometry | 1 | 2015 | 1 | 0.140 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2015 | 4 | 0.140 |
Why?
|
| Enzyme Activation | 5 | 2005 | 126 | 0.140 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 64 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2016 | 281 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 98 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 109 | 0.130 |
Why?
|
| Neurons | 1 | 2019 | 394 | 0.130 |
Why?
|
| Ethanol | 1 | 2017 | 185 | 0.130 |
Why?
|
| Gene Expression | 1 | 2016 | 332 | 0.130 |
Why?
|
| Nitric Oxide | 2 | 2006 | 116 | 0.130 |
Why?
|
| Cyclic AMP | 1 | 1994 | 40 | 0.130 |
Why?
|
| Calcium | 2 | 1994 | 296 | 0.130 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2014 | 1 | 0.130 |
Why?
|
| Lim Kinases | 1 | 2014 | 1 | 0.130 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2014 | 8 | 0.120 |
Why?
|
| Sulfonamides | 1 | 1994 | 65 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 249 | 0.120 |
Why?
|
| Ionomycin | 2 | 1994 | 4 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 23 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2014 | 170 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 23 | 0.120 |
Why?
|
| Rats | 3 | 2014 | 1604 | 0.120 |
Why?
|
| Endothelium, Vascular | 3 | 2012 | 145 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 57 | 0.120 |
Why?
|
| Cell Polarity | 1 | 2013 | 14 | 0.120 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 3 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 83 | 0.120 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2013 | 5 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2014 | 147 | 0.120 |
Why?
|
| Mutation | 2 | 2014 | 466 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 18 | 0.110 |
Why?
|
| Toxicity Tests | 1 | 2012 | 11 | 0.110 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 18 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 36 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 36 | 0.110 |
Why?
|
| Quercetin | 1 | 2012 | 8 | 0.110 |
Why?
|
| Carotid Artery Injuries | 1 | 2012 | 9 | 0.110 |
Why?
|
| Hyperplasia | 1 | 2012 | 38 | 0.110 |
Why?
|
| RNA Interference | 1 | 2012 | 76 | 0.110 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 6 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 9 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2003 | 30 | 0.110 |
Why?
|
| Adiponectin | 1 | 2012 | 103 | 0.100 |
Why?
|
| Antioxidants | 3 | 2012 | 114 | 0.100 |
Why?
|
| Iron | 1 | 2012 | 113 | 0.100 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 88 | 0.100 |
Why?
|
| Binding, Competitive | 2 | 2005 | 38 | 0.100 |
Why?
|
| Calcimycin | 2 | 1990 | 7 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 50 | 0.100 |
Why?
|
| Immunoblotting | 2 | 2008 | 50 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 82 | 0.100 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 43 | 0.100 |
Why?
|
| Vascular Patency | 1 | 2010 | 66 | 0.100 |
Why?
|
| Pyrrolidines | 1 | 2010 | 13 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 250 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2010 | 97 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2010 | 130 | 0.090 |
Why?
|
| Brain | 1 | 2017 | 930 | 0.090 |
Why?
|
| SRS-A | 1 | 1990 | 1 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 107 | 0.090 |
Why?
|
| Transduction, Genetic | 2 | 2007 | 42 | 0.090 |
Why?
|
| Eosinophils | 1 | 1990 | 48 | 0.090 |
Why?
|
| Ferric Compounds | 1 | 2009 | 14 | 0.090 |
Why?
|
| Culture Media, Serum-Free | 2 | 2000 | 15 | 0.090 |
Why?
|
| Streptozocin | 1 | 2009 | 8 | 0.090 |
Why?
|
| Urinalysis | 1 | 2009 | 19 | 0.090 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 21 | 0.090 |
Why?
|
| Free Radical Scavengers | 2 | 2017 | 11 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2009 | 12 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 532 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2012 | 327 | 0.090 |
Why?
|
| Scavenger Receptors, Class B | 2 | 2006 | 12 | 0.090 |
Why?
|
| Probability | 1 | 2009 | 150 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2012 | 449 | 0.090 |
Why?
|
| Models, Chemical | 2 | 2006 | 30 | 0.090 |
Why?
|
| Random Allocation | 1 | 2009 | 213 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 726 | 0.080 |
Why?
|
| Receptors, Scavenger | 3 | 2005 | 7 | 0.080 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2008 | 6 | 0.080 |
Why?
|
| Amifostine | 1 | 2008 | 2 | 0.080 |
Why?
|
| Radiation-Protective Agents | 1 | 2008 | 5 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 454 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 11 | 0.080 |
Why?
|
| Stem Cells | 1 | 2010 | 292 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1379 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 104 | 0.080 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2007 | 5 | 0.080 |
Why?
|
| Apolipoproteins E | 2 | 2005 | 97 | 0.080 |
Why?
|
| Genistein | 2 | 2006 | 14 | 0.080 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 15 | 0.080 |
Why?
|
| Cytosol | 1 | 2007 | 25 | 0.080 |
Why?
|
| Retroviridae | 1 | 2007 | 25 | 0.080 |
Why?
|
| Kidney | 1 | 2011 | 485 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2008 | 149 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 97 | 0.070 |
Why?
|
| Soy Foods | 1 | 2006 | 5 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2007 | 118 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 228 | 0.070 |
Why?
|
| Acute-Phase Proteins | 1 | 2006 | 10 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2007 | 108 | 0.070 |
Why?
|
| Sepsis | 1 | 2008 | 146 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 114 | 0.070 |
Why?
|
| Ribosomal Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Proline | 1 | 2006 | 10 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2006 | 26 | 0.070 |
Why?
|
| Rabbits | 3 | 2012 | 185 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 28 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 422 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2006 | 75 | 0.070 |
Why?
|
| Diamide | 1 | 2005 | 3 | 0.070 |
Why?
|
| Glutathione Disulfide | 1 | 2005 | 2 | 0.070 |
Why?
|
| Fluoresceins | 1 | 2005 | 8 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 69 | 0.070 |
Why?
|
| Carmustine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Retinal Vessels | 2 | 2016 | 18 | 0.070 |
Why?
|
| Electrons | 1 | 2005 | 11 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 40 | 0.070 |
Why?
|
| Quinolinium Compounds | 1 | 2005 | 1 | 0.070 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2005 | 4 | 0.070 |
Why?
|
| Cytochalasin D | 1 | 2005 | 3 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2017 | 514 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 36 | 0.070 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 87 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2005 | 30 | 0.060 |
Why?
|
| Lasers | 2 | 2012 | 19 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 4 | 0.060 |
Why?
|
| Polymers | 1 | 2005 | 59 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2005 | 97 | 0.060 |
Why?
|
| Homocysteine | 1 | 2004 | 15 | 0.060 |
Why?
|
| Scattering, Radiation | 2 | 2015 | 7 | 0.060 |
Why?
|
| COS Cells | 2 | 2004 | 28 | 0.060 |
Why?
|
| Light | 2 | 2015 | 25 | 0.060 |
Why?
|
| Biological Transport | 2 | 2009 | 62 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2006 | 859 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2006 | 259 | 0.060 |
Why?
|
| Uncoupling Agents | 1 | 2003 | 1 | 0.060 |
Why?
|
| Chromans | 1 | 2003 | 5 | 0.060 |
Why?
|
| Cytoprotection | 1 | 2003 | 5 | 0.060 |
Why?
|
| Superoxides | 1 | 2003 | 17 | 0.060 |
Why?
|
| Oxidants | 1 | 2002 | 15 | 0.060 |
Why?
|
| Antibodies | 1 | 2003 | 53 | 0.060 |
Why?
|
| Adult | 3 | 2006 | 8420 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2012 | 66 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2012 | 18 | 0.050 |
Why?
|
| Blood Physiological Phenomena | 1 | 2000 | 1 | 0.050 |
Why?
|
| Poly I | 1 | 2000 | 1 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 4 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2000 | 7 | 0.050 |
Why?
|
| Ceramides | 1 | 2000 | 9 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2000 | 7 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 12 | 0.050 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 1991 | 6 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2014 | 573 | 0.050 |
Why?
|
| Leukocytes | 1 | 2001 | 52 | 0.050 |
Why?
|
| Culture Media | 1 | 2000 | 39 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2000 | 51 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 51 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2001 | 71 | 0.050 |
Why?
|
| Middle Aged | 3 | 2006 | 10829 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 1991 | 72 | 0.050 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 9 | 0.050 |
Why?
|
| Biotechnology | 1 | 2000 | 6 | 0.050 |
Why?
|
| DNA Primers | 1 | 2000 | 87 | 0.050 |
Why?
|
| Plasmids | 1 | 2000 | 48 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2000 | 19 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 1991 | 89 | 0.050 |
Why?
|
| Cell Division | 1 | 2000 | 97 | 0.050 |
Why?
|
| Base Sequence | 1 | 2000 | 240 | 0.040 |
Why?
|
| NADP | 1 | 2019 | 9 | 0.040 |
Why?
|
| DNA | 1 | 2000 | 204 | 0.040 |
Why?
|
| Cell Communication | 1 | 2019 | 30 | 0.040 |
Why?
|
| Phagocytosis | 1 | 1998 | 9 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 196 | 0.040 |
Why?
|
| Alloxan | 1 | 1998 | 1 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 1998 | 49 | 0.040 |
Why?
|
| Dithiothreitol | 1 | 1998 | 8 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 21 | 0.040 |
Why?
|
| Neuralgia | 1 | 2019 | 48 | 0.040 |
Why?
|
| Leukemia P388 | 1 | 1997 | 2 | 0.040 |
Why?
|
| Buthionine Sulfoximine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Antimetabolites | 1 | 2017 | 10 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2017 | 11 | 0.040 |
Why?
|
| Microchemistry | 1 | 1997 | 5 | 0.040 |
Why?
|
| Densitometry | 1 | 1997 | 8 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 280 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 152 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1994 | 39 | 0.040 |
Why?
|
| Arterioles | 1 | 2016 | 12 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1994 | 37 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 22 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 572 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 172 | 0.040 |
Why?
|
| Cytokines | 1 | 2017 | 243 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1995 | 9 | 0.030 |
Why?
|
| CHO Cells | 2 | 2006 | 25 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cricetinae | 2 | 2006 | 58 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 167 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1994 | 6 | 0.030 |
Why?
|
| Phospholipids | 1 | 1994 | 26 | 0.030 |
Why?
|
| Monocrotaline | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 6 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 815 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 1994 | 3 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1994 | 9 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1994 | 16 | 0.030 |
Why?
|
| Indoles | 1 | 2014 | 58 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 55 | 0.030 |
Why?
|
| Phospholipases A | 2 | 1991 | 28 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2014 | 103 | 0.030 |
Why?
|
| Arachidonic Acids | 2 | 1991 | 23 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 322 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 610 | 0.030 |
Why?
|
| Acids | 1 | 2012 | 2 | 0.030 |
Why?
|
| Solutions | 1 | 2012 | 26 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Protein Stability | 1 | 2012 | 26 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 73 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2012 | 40 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 226 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2012 | 80 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2012 | 77 | 0.030 |
Why?
|
| Infrared Rays | 1 | 2012 | 18 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 33 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 747 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 27 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2012 | 66 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 138 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 462 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 339 | 0.020 |
Why?
|
| Phospholipases | 1 | 1990 | 2 | 0.020 |
Why?
|
| Isoflavones | 2 | 2006 | 65 | 0.020 |
Why?
|
| Nigericin | 1 | 1990 | 2 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2010 | 24 | 0.020 |
Why?
|
| Buffers | 1 | 1990 | 9 | 0.020 |
Why?
|
| Horses | 1 | 1990 | 13 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 53 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 2 | 0.020 |
Why?
|
| Magnetics | 1 | 2009 | 5 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 32 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 42 | 0.020 |
Why?
|
| Integrins | 1 | 2009 | 20 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 199 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 6 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 18 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 113 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 160 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 41 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2008 | 48 | 0.020 |
Why?
|
| Kinetics | 2 | 2002 | 205 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2007 | 125 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 680 | 0.020 |
Why?
|
| Prealbumin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Dairy Products | 1 | 2006 | 12 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2006 | 10 | 0.020 |
Why?
|
| Beverages | 1 | 2006 | 19 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2006 | 21 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2007 | 92 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2006 | 50 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2006 | 64 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 76 | 0.020 |
Why?
|
| Endotoxins | 1 | 2006 | 36 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2006 | 53 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 80 | 0.020 |
Why?
|
| Energy Intake | 1 | 2006 | 120 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 248 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 9 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 12 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 23 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 33 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 232 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 37 | 0.020 |
Why?
|
| Ligands | 1 | 2005 | 81 | 0.020 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2004 | 6 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2006 | 501 | 0.020 |
Why?
|
| Binding Sites | 1 | 2005 | 125 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2004 | 8 | 0.020 |
Why?
|
| Biological Availability | 1 | 2004 | 21 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2004 | 34 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 195 | 0.020 |
Why?
|
| Liver | 1 | 2007 | 464 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 13 | 0.010 |
Why?
|
| Thioredoxins | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 100 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2002 | 90 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 2004 | 196 | 0.010 |
Why?
|
| Dactinomycin | 2 | 1991 | 10 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 881 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1991 | 7 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1991 | 35 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1991 | 32 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1991 | 158 | 0.010 |
Why?
|
| Diglycerides | 1 | 1990 | 5 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 1990 | 22 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1991 | 249 | 0.010 |
Why?
|